Find information on Industry Analysis Report

Posts tagged ‘Multiple Sclerosis’

Forecast and analysis on the Multiple Sclerosis Market

Over the next five years, the global multiple sclerosis (MS) market is set to grow from $12.3 billion in 2011 to $17.3 billion in 2016. Primary drivers of this growth will be the entry of new pipeline therapies, satisfying the unmet needs of convenient administration and more efficacious therapy, and continued uptake of existing therapies.

Therapy Trends Consensus Outlook: Multiple Sclerosis analyses the global MS market players and products of today and tomorrow. Start mapping your market parameters with access to the following comprehensive resources:
* An in-depth 5-year forecast report based on analyst consensus, mapping the impact of future events to predicted product performance
* A detailed forecast data analysis spreadsheet model comparing critical market parameters including
* Timely event-driven market forecast report and data analysis updates over the next 12 months

Mapping Future Events to Product Sales Forecasts
The forecast analysis report component of Consensus Outlook: Multiple Sclerosis delivers a rich analysis of product-level sales forecast data and of the future events that underpin the forecasts. The product of meticulous FirstWord research, its historical sales data (2006–11) is based on company information, and the five-year (2012-16) product level sales forecasts are consensus projections derived from a comprehensive selection of continually assessed equity research reports.

The report combines independent, unbiased, accurate forecasts with invaluable insights into factors that impact future product performance, backed-up by research of analysts who have an unrivalled level of intimacy with the market, the players, their products and their strategies.

Report features:
* Historical MS sales from 2006–2011
* Forecast MS sales from 2012-2016
* Key competitors and drug developers
* Predicted product positioning
* Current and late-stage pipeline drugs
* Future event mapping to forecast data points
* Comparative clinical trial results

Interactive Product and Market Forecast Data Model
FirstWord’s MS forecast data model allows to you examine detailed Excel spreadsheets to quickly compare various market parameters.
* Market size
* Product sales
* Company forecasts
* Company, brand, and drug class
* Mechanism of action
* Future events

Forecasts and Analysis Updated Within Days of Major Market Events
Stay a step ahead with Therapy Trends Consensus Outlook updates. Over the next 12 months, you will receive updated market analysis and forecast reports each time a major market event breaks. Updates will be delivered straight into your inbox within days of each event’s occurrence.

Whether it’s a predicted product approval or an unexpected late stage failure, Therapy Trends has the resources and knowledge to keep you up to date with the latest market analysis.

Understand the Unique Benefits of Consensus Outlook Evaluate future sales forecasts and predicted market growth Map your market parameters and chart commercial prospects Assess market share by company and product Tailor your strategic and investment focus based on the competition Set proactive launch and branding strategies Keep up with event-driven market data updates

For more information kindly visit :
Report on Therapy Trends: Multiple Sclerosis – KOL Insight and Consensus Outlook Modules

Or

Bharat Book Bureau
Tel: +91 22 27810772 / 27810773
Fax: + 91 22 27812290
Email: info@bharatbook.com
Website: www.bharatbook.com
Follow us on twitter: http://twitter.com/#!/Sandhya3B
http://3marketresearchreport.blogspot.in/

Report on Therapy Trends: Multiple Sclerosis

An incisive report and dynamic analyst briefing service delivering insight from the most influential Multiple Sclerosis (MS) Key Opinion Leaders to map the current treatment landscape and analyse future trends.

Multiple Sclerosis: On the cusp of a treatment revolution
The year 2012 will see landmark changes in the treatment of MS. Gilenya, the first novel drug in five years, is to be joined by three new products; BG-12 from Biogen Idec, Sanofi’s Aubagio and Genzyme’s Lemtrada. These drugs will partially satisfy substantial unmet needs of convenient administration and more efficacious therapy to drive unprecedented market growth.

Driven by in-depth interviews with the world’s leading multiple sclerosis KOLs, Therapy Trends: Multiple Sclerosis uncovers how the current treatment landscape will be impacted by significant future events, with particular focus on pipeline therapies and how these will modify the way MS is managed by neurologists in the future.

Drive your strategic decision-making with inside intelligence

Therapy Trends: Multiple Sclerosis disseminates critical opinion and analysis to provide premier research.
* We cut to the heart of market-changing events and eliminate superfluous background information so you can focus on developments of greatest strategic impact and reduce your reaction time
* Our unique thought-leader selection matrix identifies the most influential KOLs in MS to deliver the perspectives vital in giving you a competitive edge, enabling informed decision-making and planning
* Detailed analysis of marketed and pipeline drugs helps you understand the products that will shape the future MS market
* KOL consensus on the future treatment algorithm offers a window into the future changes in medical evidence and clinical practice
* Uncovering KOLs’ opinions on unmet needs enables you to identify potential commercial opportunities
* Dynamic report updates evaluate the market impact of key events from KOL perspectives, allowing you to react to significant MS market developments within days of events occurring

Critical questions answered
Our MS KOLs are selected according to their level of engagement and influence within the pharmaceutical industry and their scientific standing. FirstWord’s unique KOL scoring system enables identification of KOLs with the greatest knowledge of how MS treatment will evolve and shape the future landscape.

* What are the key unmet needs? There is a high risk, high reward opportunity in the development of a therapy with efficacy for progressive subtypes.
* How will therapies will be positioned against each other in the future of MS treatment? Biogen’s new oral therapy BG-12 is expected to usurp the current market leaders and become the first-line therapy of choice.
* How will treatment developments play out in the near future? Biogen’s activity in broadening its robust pipeline shows its resolve in maintaining its leading position in MS.
* Is there potential for new players in the lucrative MS market? New entrants are set to capture significant share and cannibalise sales of the leading drugs.
* Where will Sanofi’s Lemtrada and Aubagio be positioned in treatment? Pricing and safety will play a large part in determining uptake of this highly effective drug
* How will the launch of biosimilars affect prescribing behavior? Pricing will be a key determinant in positioning and uptake
* How will Novartis’s Gilenya be affected by recent safety concerns? Long-term concerns have kept it from being the first line therapy.
* Will the new John Cunningham Virus test encourage earlier adoption of Tysabri? This offers the first example of personalised medicine; a trend that will aid uptake in future.

For more information kindly visit :
Report on Therapy Trends: Multiple Sclerosis

Or

Bharat Book Bureau
Tel: +91 22 27810772 / 27810773
Fax: + 91 22 27812290
Email: info@bharatbook.com
Website: www.bharatbook.com
Follow us on twitter: http://twitter.com/#!/Sandhya3B
http://3marketresearchreport.blogspot.in/

Report on Consensus Outlook: Multiple Sclerosis

Over the next five years, the global multiple sclerosis (MS) market is set to grow from $12.3 billion in 2011 to $17.3 billion in 2016. Primary drivers of this growth will be the entry of new pipeline therapies, satisfying the unmet needs of convenient administration and more efficacious therapy, and continued uptake of existing therapies.

Therapy Trends Consensus Outlook: Multiple Sclerosis analyses the global MS market players and products of today and tomorrow. Start mapping your market parameters with access to the following comprehensive resources:

* An in-depth 5-year forecast report based on analyst consensus, mapping the impact of future events to predicted product performance
* A detailed forecast data analysis spreadsheet model comparing critical market parameters including market size, product sales, market shares and competitive status over the period 2006 to 2016
* Timely event-driven market forecast report and data analysis updates over the next 12 months

Understand the Unique Benefits of Consensus Outlook
* Evaluate future sales forecasts and predicted market growth
* Map your market parameters and chart commercial prospects
* Assess market share by company and product
* Tailor your strategic and investment focus based on the competition
* Set proactive launch and branding strategies
* Keep up with event-driven market data updates

Mapping Future Events to Product Sales Forecasts
The forecast analysis report component of Consensus Outlook: Multiple Sclerosis delivers a rich analysis of product-level sales forecast data and of the future events that underpin the forecasts. The product of meticulous FirstWord research, its historical sales data (2006–11) is based on company information, and the five-year (2012-16) product level sales forecasts are consensus projections derived from a comprehensive selection of continually assessed equity research reports.

The report combines independent, unbiased, accurate forecasts with invaluable insights into factors that impact future product performance, backed-up by research of analysts who have an unrivalled level of intimacy with the market, the players, their products and their strategies.

Report features:
* Historical MS sales from 2006–2011
* Forecast MS sales from 2012-2016
* Key competitors and drug developers
* Predicted product positioning
* Current and late-stage pipeline drugs
* Future event mapping to forecast data points
* Comparative clinical trial results

An approach backed by unrivalled knowledge and market intimacy
For each Therapy Trends report, FirstWord analysts produce a data analysis module, a Consensus Outlook, which provides annual historical and forecast, product-level sales data. Historical sales data is derived from company information, while the five-year (2012-16) product level sales forecasts are consensus projections derived from a comprehensive selection of continually assessed equity research reports.

Once a Therapy Trends data module is published, FirstWord analysts subsequently collate and evaluate the latest relevant reports published by equity research analysts and feed relevant updated forecasts into the Therapy Trends forecast model.

Consensus forecasts derived from the leading equity research analysts reflect the most up-to-date assessment of the pharmaceutical market, with equity analyst models updated to reflect a broad spectrum of events and catalysts, which range from the publication of quarterly financial results to in-depth discussions with leading key opinion leaders (KOLs). Consensus forecasts also act as an excellent benchmark against which other projections – produced either internally or by other third parties – can be assessed.

For more information kindly visit :
Report on Consensus Outlook: Multiple Sclerosis

Or

Bharat Book Bureau
Tel: +91 22 27810772 / 27810773
Fax: + 91 22 27812290
Email: info@bharatbook.com
Website: www.bharatbook.com
Follow us on twitter: http://twitter.com/#!/Sandhya3B
http://3marketresearchreport.blogspot.in/

Tag Cloud